Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions

Ashkan Shoamanesh, Lesly A. Pearce, Carlos Bazan, Luciana Catanese, Leslie A. McClure, Mukul Sharma, Joan Marti-Fabregas, David C. Anderson, Carlos S. Kase, Robert G. Hart, Oscar R. Benavente, on behalf of the SPS3 Trial Investigators

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Objective: To characterize cerebral microbleeds (CMBs) in lacunar stroke patients in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial and to assess their relationship with recurrent stroke and death, and response to assigned treatment. Methods: SPS3 is a randomized, clinical trial conducted between 2003 and 2011. Patients with recent magnetic resonance imaging (MRI)-documented lacunar infarcts were randomly assigned in a factorial design to target levels of systolic blood pressure (130–149mmHg vs <130mmHg; open label) and to antiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded). The current analysis involves 1,278 trial participants who had a baseline axial T2*-weighted gradient echo MRI sequence allowing for CMB detection. Results: CMBs were present in 30% of 1,278 patients (mean age = 63 years). Male gender (odds ratio [OR] = 1.7, 95% confidence interval [CI] = 1.3–2.3), history of hypertension (OR = 1.6, 95% CI = 1.2–2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI = 1.1–1.4), nondiabetic status (OR = 1.4, 95% CI = 1.1–1.9), multiple old lacunar infarcts (OR = 1.9, 95% CI = 1.5–2.5), and moderate (OR = 1.7, 95% CI = 1.2–2.3) or severe (OR = 4.2, 95% CI = 3.0–5.9) white matter hyperintensities on MRI were independently associated with CMBs. During a mean follow-up of 3.3 years, overall stroke recurrence was 2.5% per patient-year. Patients with CMBs had an adjusted 2-fold increased risk of recurrent stroke (hazard ratio = 2.1, 95% CI = 1.4–3.1). CMBs were not a risk factor for death. There were no statistically significant interactions between CMBs and treatment assignments. Interpretation: Patients with lacunar stroke and CMBs likely harbor a more advanced form of cerebral small vessel disease in need of efficacious therapeutic strategies. Ann Neurol 2017;82:196–207.

Original languageEnglish (US)
Pages (from-to)196-207
Number of pages12
JournalAnnals of Neurology
Volume82
Issue number2
DOIs
StatePublished - Aug 2017

Bibliographical note

Funding Information:
Supported by a cooperative agreement from the NIH National Institute of Neurological Disorders and Stroke (U01 NS38529-04A1). A.S. is supported by an endowed chair from the Marta and Owen Boris Foundation.

Publisher Copyright:
© 2017 American Neurological Association

Fingerprint

Dive into the research topics of 'Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions'. Together they form a unique fingerprint.

Cite this